Literature DB >> 8101004

Selective coupling of methotrexate to peptide hormone carriers through a gamma-carboxamide linkage of its glutamic acid moiety: benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate activation in salt coupling.

A Nagy1, B Szoke, A V Schally.   

Abstract

A convenient synthetic method is described for the preparation of peptide-methotrexate (MTX) conjugates in which MTX is coupled selectively through the gamma-carboxyl group of its glutamic acid moiety to a free amino group in peptide analogs. The syntheses of a somatostatin analog-MTX conjugate (MTX-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2) (AN-51) and two conjugates of analogs of luteinizing hormone-releasing hormone (LH-RH) with MTX [Glp-His-Trp-Ser-Tyr-D-Lys(MTX)-Leu-Arg-Pro-Gly-NH2] (AJ-04) and [Ac-Ser-Tyr-D-Lys(MTX)-Leu-Arg-Pro-NH-Et] AJ-51 are presented as examples. Benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP reagent) was used in the synthesis for activation of 4-amino-4-deoxy-N10-methylpteroic acid, which reacted with the potassium salt of glutamic acid alpha-tert-butyl ester in dimethyl sulfoxide to form the suitably protected MTX derivative. This synthesis provides an example of the high suitability of BOP reagent for the salt-coupling method. The selectively protected MTX derivative was then coupled to the different peptide carriers and deprotected under relatively mild conditions by trifluoroacetic acid. The conjugates of MTX with hormonal analogs are suitable for targeting to various tumors that possess receptors for the peptide moieties.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101004      PMCID: PMC46931          DOI: 10.1073/pnas.90.13.6373

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  13 in total

1.  Synthesis of methotrexate-antibody conjugates by regiospecific coupling and assessment of drug and antitumor activities.

Authors:  J Kralovec; G Spencer; A H Blair; M Mammen; M Singh; T Ghose
Journal:  J Med Chem       Date:  1989-11       Impact factor: 7.446

2.  Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6.

Authors:  S Bajusz; T Janaky; V J Csernus; L Bokser; M Fekete; G Srkalovic; T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

3.  Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone.

Authors:  S Bajusz; T Janaky; V J Csernus; L Bokser; M Fekete; G Srkalovic; T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

4.  Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.

Authors:  R Z Cai; B Szoke; R Lu; D Fu; T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

5.  Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties.

Authors:  T Janáky; A Juhász; Z Rékási; P Serfözö; J Pinski; L Bokser; G Srkalovic; S Milovanovic; T W Redding; G Halmos
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

6.  Methotrexate analogues. 14. Synthesis of new gamma-substituted derivatives as dihydrofolate reductase inhibitors and potential anticancer agents.

Authors:  A Rosowsky; R Forsch; J Uren; M Wick
Journal:  J Med Chem       Date:  1981-12       Impact factor: 7.446

Review 7.  Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.

Authors:  A V Schally; G Srkalovic; B Szende; T W Redding; T Janaky; A Juhasz; E Korkut; R Z Cai; K Szepeshazi; S Radulovic
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-20       Impact factor: 4.292

8.  Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. I. General features and binding of methotrexate.

Authors:  J T Bolin; D J Filman; D A Matthews; R C Hamlin; J Kraut
Journal:  J Biol Chem       Date:  1982-11-25       Impact factor: 5.157

9.  Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.

Authors:  S Radulovic; A Nagy; B Szoke; A V Schally
Journal:  Cancer Lett       Date:  1992-03-15       Impact factor: 8.679

10.  Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups.

Authors:  T Janáky; A Juhász; S Bajusz; V Csernus; G Srkalovic; L Bokser; S Milovanovic; T W Redding; Z Rékási; A Nagy
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-01       Impact factor: 11.205

View more
  5 in total

Review 1.  Host-pathogen interactions: the seduction of molecular cross talk.

Authors:  P Sansonetti
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

2.  Design of riboflavin-presenting PAMAM dendrimers as a new nanoplatform for cancer-targeted delivery.

Authors:  Thommey P Thomas; Seok Ki Choi; Ming-Hsin Li; Alina Kotlyar; James R Baker
Journal:  Bioorg Med Chem Lett       Date:  2010-07-08       Impact factor: 2.823

3.  Copper-free click conjugation of methotrexate to a PAMAM dendrimer platform.

Authors:  Baohua Huang; Ankur Desai; Hong Zong; Shengzhuang Tang; Pascale Leroueil; James R Baker
Journal:  Tetrahedron Lett       Date:  2011-03-30       Impact factor: 2.415

4.  PET/NIR-II fluorescence imaging and image-guided surgery of glioblastoma using a folate receptor α-targeted dual-modal nanoprobe.

Authors:  Xiaojing Shi; Pengfei Xu; Caiguang Cao; Zhen Cheng; Jie Tian; Zhenhua Hu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07-15       Impact factor: 10.057

5.  The yeast three-hybrid system as an experimental platform to identify proteins interacting with small signaling molecules in plant cells: potential and limitations.

Authors:  Stéphanie Cottier; Timon Mönig; Zheming Wang; Jiří Svoboda; Wilhelm Boland; Markus Kaiser; Erich Kombrink
Journal:  Front Plant Sci       Date:  2011-12-26       Impact factor: 5.753

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.